Logo image of SNDX

SYNDAX PHARMACEUTICALS INC (SNDX) Stock Fundamental Analysis

NASDAQ:SNDX - Nasdaq - US87164F1057 - Common Stock - Currency: USD

16.38  +0.39 (+2.44%)

After market: 16.38 0 (0%)

Fundamental Rating

2

SNDX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of SNDX is average, but there are quite some concerns on its profitability. SNDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SNDX has reported negative net income.
In the past year SNDX has reported a negative cash flow from operations.
SNDX had negative earnings in 4 of the past 5 years.
In the past 5 years SNDX reported 4 times negative operating cash flow.
SNDX Yearly Net Income VS EBIT VS OCF VS FCFSNDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

SNDX has a Return On Assets of -69.76%. This is in the lower half of the industry: SNDX underperforms 65.54% of its industry peers.
With a Return On Equity value of -81.07%, SNDX perfoms like the industry average, outperforming 52.04% of the companies in the same industry.
Industry RankSector Rank
ROA -69.76%
ROE -81.07%
ROIC N/A
ROA(3y)-19.55%
ROA(5y)-34.5%
ROE(3y)-21.21%
ROE(5y)-54.28%
ROIC(3y)N/A
ROIC(5y)N/A
SNDX Yearly ROA, ROE, ROICSNDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNDX Yearly Profit, Operating, Gross MarginsSNDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

SNDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SNDX has more shares outstanding
The debt/assets ratio for SNDX is higher compared to a year ago.
SNDX Yearly Shares OutstandingSNDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
SNDX Yearly Total Debt VS Total AssetsSNDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

SNDX has an Altman-Z score of 8.97. This indicates that SNDX is financially healthy and has little risk of bankruptcy at the moment.
SNDX has a better Altman-Z score (8.97) than 85.97% of its industry peers.
SNDX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, SNDX is in line with its industry, outperforming 49.56% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.97
ROIC/WACCN/A
WACCN/A
SNDX Yearly LT Debt VS Equity VS FCFSNDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

SNDX has a Current Ratio of 6.99. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
SNDX's Current ratio of 6.99 is fine compared to the rest of the industry. SNDX outperforms 66.96% of its industry peers.
A Quick Ratio of 6.99 indicates that SNDX has no problem at all paying its short term obligations.
SNDX has a Quick ratio of 6.99. This is in the better half of the industry: SNDX outperforms 67.14% of its industry peers.
Industry RankSector Rank
Current Ratio 6.99
Quick Ratio 6.99
SNDX Yearly Current Assets VS Current LiabilitesSNDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

SNDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.70%.
EPS 1Y (TTM)-40.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SNDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.66%
EPS Next 2Y-15.96%
EPS Next 3Y-1.41%
EPS Next 5Y15.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNDX Yearly Revenue VS EstimatesSNDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SNDX Yearly EPS VS EstimatesSNDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNDX. In the last year negative earnings were reported.
Also next year SNDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDX Price Earnings VS Forward Price EarningsSNDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNDX Per share dataSNDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.96%
EPS Next 3Y-1.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNDAX PHARMACEUTICALS INC

NASDAQ:SNDX (2/21/2025, 8:00:02 PM)

After market: 16.38 0 (0%)

16.38

+0.39 (+2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)03-05 2025-03-05/amc
Inst Owners117.23%
Inst Owner Change12.92%
Ins Owners1.25%
Ins Owner Change11.09%
Market Cap1.40B
Analysts85.71
Price Target36.65 (123.75%)
Short Float %27.26%
Short Ratio8.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.93%
Min EPS beat(2)13.67%
Max EPS beat(2)14.2%
EPS beat(4)4
Avg EPS beat(4)11.02%
Min EPS beat(4)1.39%
Max EPS beat(4)14.84%
EPS beat(8)8
Avg EPS beat(8)9.7%
EPS beat(12)12
Avg EPS beat(12)52.74%
EPS beat(16)15
Avg EPS beat(16)39.56%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.98%
PT rev (3m)-1.25%
EPS NQ rev (1m)-4080.17%
EPS NQ rev (3m)-4080.17%
EPS NY rev (1m)-12.22%
EPS NY rev (3m)13.85%
Revenue NQ rev (1m)-25.24%
Revenue NQ rev (3m)-31.22%
Revenue NY rev (1m)-0.53%
Revenue NY rev (3m)177.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.39
P/FCF N/A
P/OCF N/A
P/B 3.82
P/tB 3.82
EV/EBITDA N/A
EPS(TTM)-3.63
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS0.19
BVpS4.29
TBVpS4.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.76%
ROE -81.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.55%
ROA(5y)-34.5%
ROE(3y)-21.21%
ROE(5y)-54.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.99
Quick Ratio 6.99
Altman-Z 8.97
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)108.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.25%
EPS Next Y-9.66%
EPS Next 2Y-15.96%
EPS Next 3Y-1.41%
EPS Next 5Y15.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.32%
EBIT Next 3Y2.15%
EBIT Next 5YN/A
FCF growth 1Y-2437.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2470.67%
OCF growth 3YN/A
OCF growth 5YN/A